139 related articles for article (PubMed ID: 28692117)
1. Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues.
Xia HB; Cui HW; Su L; Zhang ZH; Yang XY; Ning SQ; Su XL
Genet Mol Res; 2017 Jul; 16(3):. PubMed ID: 28692117
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.
Zhou X; Tolstov Y; Arslan A; Roth W; Grüllich C; Pahernik S; Hohenfellner M; Duensing S
Neoplasia; 2014 Dec; 16(12):1028-35. PubMed ID: 25499216
[TBL] [Abstract][Full Text] [Related]
3. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma.
Hirata H; Hinoda Y; Nakajima K; Kawamoto K; Kikuno N; Ueno K; Yamamura S; Zaman MS; Khatri G; Chen Y; Saini S; Majid S; Deng G; Ishii N; Dahiya R
Int J Cancer; 2011 Apr; 128(8):1793-803. PubMed ID: 20549706
[TBL] [Abstract][Full Text] [Related]
4. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
[TBL] [Abstract][Full Text] [Related]
5. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance.
Zantl N; Weirich G; Zall H; Seiffert BM; Fischer SF; Kirschnek S; Hartmann C; Fritsch RM; Gillissen B; Daniel PT; Häcker G
Oncogene; 2007 Oct; 26(49):7038-48. PubMed ID: 17486061
[TBL] [Abstract][Full Text] [Related]
6. Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma?
Masuda A; Kamai T; Abe H; Arai K; Yoshida K
Biomed Res; 2009 Jun; 30(3):171-6. PubMed ID: 19574718
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of miR-21 expression is a valuable predicator of advanced clinicopathological features and poor prognosis in patients with renal cell carcinoma through the p53/p21‑cyclin E2‑Bax/caspase-3 signaling pathway.
Liu Z; Lu Y; Xiao Y; Lu Y
Oncol Rep; 2017 Mar; 37(3):1437-1444. PubMed ID: 28184919
[TBL] [Abstract][Full Text] [Related]
8. Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.
Grabow S; Delbridge AR; Aubrey BJ; Vandenberg CJ; Strasser A
Cell Rep; 2016 Mar; 14(10):2337-47. PubMed ID: 26947081
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances.
Shu GS; Lv F; Yang ZL; Miao XY
Int J Clin Oncol; 2013 Aug; 18(4):641-50. PubMed ID: 22714709
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between PUMA and BIM expression in colorectal cancer and tumor invasion, metastasis and prognosis].
Yuan H; Tu SL; He XJ
Zhonghua Wai Ke Za Zhi; 2013 Jun; 51(6):547-51. PubMed ID: 24091272
[TBL] [Abstract][Full Text] [Related]
11. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological correlations of marrow PUMA and P53 expressions in myelodysplastic syndromes.
Bektas O; Uner A; Buyukasik Y; Uz B; Bozkurt S; Eliacik E; Işik A; Haznedaroglu IC; Goker H; Demiroglu H; Aksu S; Ozcebe OI; Sayinalp N
APMIS; 2015 May; 123(5):445-51. PubMed ID: 25846496
[TBL] [Abstract][Full Text] [Related]
13. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
Hofmockel G; Wittmann A; Dammrich J; Bassukas ID
Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma.
Cho DS; Joo HJ; Oh DK; Kang JH; Kim YS; Lee KB; Kim SJ
Yonsei Med J; 2005 Feb; 46(1):133-40. PubMed ID: 15744816
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma.
Yu Q; Liu ZY; Chen Q; Lin JS
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):494-500. PubMed ID: 27465322
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
Du P; Ye L; Yang Y; Jiang WG
Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
[TBL] [Abstract][Full Text] [Related]
18. Gastric cancer and concomitant renal cancer: a systematic immunohistochemical and molecular analysis.
Betge J; Pollheimer MJ; Schlemmer A; Hoefler G; Langner C
Oncol Rep; 2011 Sep; 26(3):567-75. PubMed ID: 21687951
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance.
Cai W; Li Q; Yang Z; Miao X; Wen Y; Huang S; Ouyang J
Clin Transl Oncol; 2013 Oct; 15(10):818-24. PubMed ID: 23475628
[TBL] [Abstract][Full Text] [Related]
20. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
Int J Cancer; 1996 May; 66(3):322-5. PubMed ID: 8621251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
